BioAtla, Inc. (BCAB) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: BioAtla, Inc.
Reporting Period: Fiscal year ended December 31, 2024.
Business Model: Clinical-stage biopharmaceutical company developing Conditionally Active Biologics (CABs) for solid tumor cancers. CABs are designed to bind selectively to tumor targets in acidic microenvironments while remaining inactive in healthy tissue.
Key Assets: Lead candidates include mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), evalstotug (BA3071), and BA3182. The company relies on third-party contract manufacturers and has no commercial products approved for sale.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $11,000 | $0 |
| Net Loss | $(69,776) | $(123,462) |
| Operating Expenses | $84,943 | $129,687 |
| Research & Development (R&D) | $63,095 | $103,731 |
| General & Administrative (G&A) | $21,848 | $25,956 |
| Cash and Cash Equivalents (Year End) | $49,046 | $111,471 |
| Accumulated Deficit | $(486,039) | $(416,263) |
| Net Cash Used in Operating Activities | $(71,936) | $(104,015) |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $11.0 million in revenue in 2024, primarily from an upfront payment under a September 2024 license agreement with Context Therapeutics Inc. for the BA3362 asset. No revenue was recognized in 2023.
- Expense Reduction: Total operating expenses decreased by approximately $44.7 million (35%) compared to 2023.
- R&D: Decreased by $40.6 million, driven by reduced costs for pre-clinical programs (BA3142, BA3361) and clinical stage programs (mecbotamab vedotin, ozuriftamab vedotin) following Phase 2 enrollment completion.
- G&A: Decreased by $4.1 million, largely due to lower stock-based compensation and insurance costs.
- Capital Raise: In December 2024, the company completed a registered direct offering, raising approximately $9.2 million in net proceeds by issuing 9.7 million shares and accompanying warrants.
- Workforce Reduction: In March 2025 (subsequent to year-end), the company announced a workforce reduction of approximately 30% to extend its cash runway.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management estimates current cash ($49.0 million) may fund operations only into the first half of 2026. Additional financing is required to continue operations.
- Listing Status: The company received notice from Nasdaq in February 2025 regarding non-compliance with the minimum bid price requirement ($1.00 per share). It has 180 days to regain compliance or risk delisting.
- Clinical Progress:
- Mecbotamab vedotin (BA3011): FDA clearance obtained for a potentially registration-enabling Phase 2/3 trial in NSCLC.
- Ozuriftamab vedotin (BA3021): FDA Fast-Track designation granted for SCCHN.
- Evalstotug (BA3071): Phase 2 study initiated in combination with pembrolizumab.
- Unusual Items: The company recorded a $0.8 million gain on the change in fair value of warrant liabilities in 2024. A $19.8 million "Liability to Licensor" remains on the balance sheet related to the terminated BeiGene collaboration, payable as royalties on future sales.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first half of 2026" funding estimate given the recent 30% workforce reduction and potential for accelerated clinical spending.
- Nasdaq Compliance: Monitor the stock price to determine if the company will regain compliance with the $1.00 minimum bid price requirement by August 2025.
- Context Therapeutics Deal: Review the terms of the $133.5 million potential deal with Context Therapeutics to understand the likelihood of achieving future milestones beyond the initial $11.0 million recognized.
- Related Party Transactions: Scrutinize the financial impact of agreements with Himalaya Therapeutics SEZC and other entities managed by the CEO's spouse, particularly regarding royalty sharing and expense allocations.
- Warrant Liability: Assess the impact of the $3.8 million warrant liability and the potential dilution from 9.7 million warrants exercisable starting June 2025.